- STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study showsAn experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.STAT · 11d ago↗ source
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs<figure><div><img src="https://imgproxy.divecdn.com/Bdi5M4HMTn0nQ7Ww6DWMZBEaPY1McVmIyhbOSlOBYfo/g:nowe:0:194/c:1920:1085/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8zODY4NjUwMzI1M…BioPharma Dive · 11d ago↗ source
- Draig nets $65M to advance depression drug aimed at rebuilding synapsesDraig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…